61 related articles for article (PubMed ID: 16206197)
1. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.
Smeland S; Bruland OS; Hjorth L; Brosjö O; Bjerkehagen B; Osterlundh G; Jakobson A; Hall KS; Monge OR; Björk O; Alvegaard TA
Acta Orthop; 2011 Apr; 82(2):211-6. PubMed ID: 21434784
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience.
Bastard P; Cozic N; Brion R; Gaspar N; Piperno-Neumann S; Cordero C; Leculée-Thébaud E; Gomez-Mascard A; Rédini F; Marchais A; Ikonomova R; Cleirec M; Laurence V; Rigaud C; Abbas R; Verrecchia F; Brugières L; Minard-Colin V
Pediatr Blood Cancer; 2024 Jul; 71(7):e31029. PubMed ID: 38679845
[TBL] [Abstract][Full Text] [Related]
3. Prolonged 14-day continuous infusion of high-dose ifosfamide for patients with relapsed and refractory high-grade osteosarcoma: a retrospective multicentre cohort study.
Tirtei E; Campello A; Sciannameo V; Asaftei SD; Meazza C; Sironi G; Longhi A; Ibrahim T; Tamburini A; Coccoli L; Crocco F; Cagnazzo C; De Luna E; Quarello P; Berchialla P; Fagioli F
BMC Cancer; 2024 Jun; 24(1):747. PubMed ID: 38898388
[TBL] [Abstract][Full Text] [Related]
4. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.
Arndt CA; Koshkina NV; Inwards CY; Hawkins DS; Krailo MD; Villaluna D; Anderson PM; Goorin AM; Blakely ML; Bernstein M; Bell SA; Ray K; Grendahl DC; Marina N; Kleinerman ES
Clin Cancer Res; 2010 Aug; 16(15):4024-30. PubMed ID: 20576718
[TBL] [Abstract][Full Text] [Related]
5. Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma.
Yong B; Tan P; Yin J; Zou C; Xie X; Wang J; Huang G; Wang Q; Shen J
World J Surg Oncol; 2012 Sep; 10():191. PubMed ID: 22985081
[TBL] [Abstract][Full Text] [Related]
6. Metastatic osteosarcoma bowel perforation secondary to chemotherapy-induced tumour necrosis.
Bhadbhade M; Connolly E; Badiani S; Yeo D; Bhadri V
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35473702
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin Dose Deintensification in Pediatric Osteosarcoma, Is Less Better?
Halalsheh H; Abu-Hijlih R; Ismael T; Shehadeh A; Salaymeh KJ; Boheisi M; Sultan I
South Asian J Cancer; 2023 Jul; 12(3):290-296. PubMed ID: 38047045
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q
Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158
[TBL] [Abstract][Full Text] [Related]
9. Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming.
Yang Y; Peng Z; Flores ER; Kleinerman ES
Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077845
[TBL] [Abstract][Full Text] [Related]
10. Recent and Ongoing Research into Metastatic Osteosarcoma Treatments.
Harris MA; Hawkins CJ
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409176
[TBL] [Abstract][Full Text] [Related]
11. Osteosarcoma Overview.
Lindsey BA; Markel JE; Kleinerman ES
Rheumatol Ther; 2017 Jun; 4(1):25-43. PubMed ID: 27933467
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.
Hattinger CM; Vella S; Tavanti E; Fanelli M; Picci P; Serra M
Pharmacogenomics; 2016 Dec; 17(18):2097-2114. PubMed ID: 27883291
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment.
van Maldegem AM; Bhosale A; Gelderblom HJ; Hogendoorn PC; Hassan AB
Clin Sarcoma Res; 2012 Jan; 2(1):5. PubMed ID: 22587841
[TBL] [Abstract][Full Text] [Related]
14. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
Chou AJ; Kleinerman ES; Krailo MD; Chen Z; Betcher DL; Healey JH; Conrad EU; Nieder ML; Weiner MA; Wells RJ; Womer RB; Meyers PA;
Cancer; 2009 Nov; 115(22):5339-48. PubMed ID: 19637348
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxicity of chemotherapeutic and biologic agents in children with cancer.
De Braganca KC; Packer RJ
Curr Neurol Neurosci Rep; 2008 Mar; 8(2):114-22. PubMed ID: 18460279
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
Patel SR; Papadopolous N; Raymond AK; Donato M; Seong CM; Yasko AW; Lewis VO; Lin PP; Champlin R; Benjamin RS
Cancer; 2004 Jul; 101(1):156-63. PubMed ID: 15222001
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.
Michelagnoli MP; Lewis IJ; Gattamaneni HR; Bailey CC; Lashford LS
Br J Cancer; 1999 Mar; 79(7-8):1174-8. PubMed ID: 10098754
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
